Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DW5121
- Development stage
- Unknown
- Lead developer
- Daewon Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DW5121 is a small molecule investigational drug developed by Daewon Pharmaceutical for the treatment of acute bronchitis. It is being studied as an oral therapy and is classified as an antibronchitic. Its precise mechanism of action has not been publicly disclosed, but it is a new molecular entity, designed to provide improved symptom control and safety for patients with acute bronchitis. DW5121 has reached Phase 3 of clinical development and has been evaluated in head-to-head studies versus DW51211 and DW51212 in patients with acute bronchitis, with endpoints focusing on the Bronchitis Severity Score[1][2][3][5].
- Other names
- DW-5121DW5121DW 5121
Beyond the preview
Go deeper on DW5121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DW5121.